[Use of adriablastine in the combined chemotherapy of breast cancer patients with bone metastases].
Twenty patients with generalized breast cancer metastasizing in bones were subjected to treatment by a combination of adriablastine with cyclophosphane or adriablastine with cyclophosphane, 5-fluoruracil, vincristine using repeat 8-day cycles with 3-week intervals between them. A considerable subjective and sympathetic improvement was noted in 13 patients. Of 14 patients in whom bone metastases were associated with tumor involvement of different soft tissues and organs the tumor regression was gained in 8 patients. Side effects in all these cases were similar and mostly related with the use of adriablastine: nausea, vomiting, alopecia.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000556:secondary; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin
Primenenie adriablastina v kombinirovannoĭ khimioterapii bol'nykh s kostnymi metastazami raka molochnoĭ zhelezy.